{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:13:50Z","timestamp":1787314430582,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5741-y","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T10:03:05Z","timestamp":1559210585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0048-6314","authenticated-orcid":false,"given":"Mark T. J.","family":"van Bussel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieta","family":"Brandsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"issue":"Suppl 5","key":"5741_CR1","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297.","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. ESMO guidelines committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2015;26(Suppl 5):v126\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdv297.","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"5741_CR2","unstructured":"European Medicines Agency. Summary of product characteristics Nivolumab. Available at https:\/\/www.ema.europa.eu\/en . Accessed 12 Sept 2018."},{"key":"5741_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/his.12537","volume":"66","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. Histopathology. 2015;66:289\u201399. https:\/\/doi.org\/10.1111\/his.12537 .","journal-title":"Histopathology."},{"key":"5741_CR4","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1074\/mcp.RA117.000037","volume":"16","author":"CA Morales-Betanzos","year":"2017","unstructured":"Morales-Betanzos CA, Lee H, Gonzalez Ericsson PI, Balko JM, Johnson DB, Zimmerman LJ, et al. Quantitative mass spectrometry analysis of PD-L1 protein expression, N -glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol Cell Proteomics. 2017;16:1705\u201317. https:\/\/doi.org\/10.1074\/mcp.RA117.000037 .","journal-title":"Mol Cell Proteomics"},{"key":"5741_CR5","unstructured":"Summary of product characteristics Ipilimumab. Available at https:\/\/www.ema.europa.eu\/en . Accessed 14 Sept 2018."},{"key":"5741_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985\u20138.","journal-title":"Science."},{"key":"5741_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030 .","journal-title":"N Engl J Med"},{"key":"5741_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2455-9","volume":"35","author":"M Kim","year":"2018","unstructured":"Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35:177. https:\/\/doi.org\/10.1007\/s11095-018-2455-9 .","journal-title":"Pharm Res"},{"key":"5741_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.it.2006.11.007","volume":"28","author":"I Bechmann","year":"2007","unstructured":"Bechmann I, Galea I, Perry VH. What is the blood-brain barrier (not)? Trends Immunol. 2007;28:5\u201311.","journal-title":"Trends Immunol"},{"key":"5741_CR10","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQM. Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro-Oncology. 2017;19:i1\u201324. https:\/\/doi.org\/10.1093\/neuonc\/now197 .","journal-title":"Neuro-Oncology"},{"key":"5741_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1021\/jm00180a022","volume":"23","author":"VA Levin","year":"1980","unstructured":"Levin VA. Relationship of octanol\/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem. 1980;23:682\u20134. https:\/\/doi.org\/10.1021\/jm00180a022 .","journal-title":"J Med Chem"},{"key":"5741_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40259-017-0248-z","volume":"31","author":"WM Pardridge","year":"2017","unstructured":"Pardridge WM. Delivery of biologics across the blood-brain barrier with molecular Trojan horse technology. BioDrugs. 2017;31:503\u201319. https:\/\/doi.org\/10.1007\/s40259-017-0248-z .","journal-title":"BioDrugs."},{"key":"5741_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1021\/ci600312d","volume":"47","author":"YH Zhao","year":"2007","unstructured":"Zhao YH, Abraham MH, Ibrahim A, Fish PV, Cole S, Lewis ML, et al. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes. J Chem Inf Model. 2007;47:170\u20135. https:\/\/doi.org\/10.1021\/ci600312d .","journal-title":"J Chem Inf Model"},{"key":"5741_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.phrs.2017.06.008","volume":"123","author":"G Gampa","year":"2017","unstructured":"Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. Drug delivery to melanoma brain metastases: can current challenges lead to new opportunities? Pharmacol Res. 2017;123:10\u201325. https:\/\/doi.org\/10.1016\/j.phrs.2017.06.008 .","journal-title":"Pharmacol Res"},{"key":"5741_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453 .","journal-title":"N Engl J Med"},{"key":"5741_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(18)30139-6 .","journal-title":"Lancet Oncol."},{"key":"5741_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623\u201335. https:\/\/doi.org\/10.1038\/nri3265 .","journal-title":"Nat Rev Immunol"},{"key":"5741_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337\u201341. https:\/\/doi.org\/10.1038\/nature14432 .","journal-title":"Nature."},{"key":"5741_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","volume":"21","author":"A Louveau","year":"2018","unstructured":"Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, Viar KE, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci. 2018;21:1380\u201391. https:\/\/doi.org\/10.1038\/s41593-018-0227-9 .","journal-title":"Nat Neurosci"},{"key":"5741_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cam4.45","volume":"2","author":"M Amit","year":"2013","unstructured":"Amit M, Laider-Trejo L, Shalom V, Shabtay-Orbach A, Krelin Y, Gil Z. Characterization of the melanoma brain metastatic niche in mice and humans. Cancer Med. 2013;2:155\u201363. https:\/\/doi.org\/10.1002\/cam4.45 .","journal-title":"Cancer Med"},{"key":"5741_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10585-012-9510-4","volume":"30","author":"AS Berghoff","year":"2013","unstructured":"Berghoff AS, Lassmann H, Preusser M, H\u00f6ftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin Exp Metastasis. 2013;30:69\u201381. https:\/\/doi.org\/10.1007\/s10585-012-9510-4 .","journal-title":"Clin Exp Metastasis"},{"key":"5741_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(12)70090-6 .","journal-title":"Lancet Oncol"},{"key":"5741_CR23","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/results?term=nivolumab+ipilimumab&type=Intr&cond=melanoma+brain+metastases&rank=4#rowId3 . Accessed 2 Jan 2019."},{"key":"5741_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","volume":"39","author":"RC Aalberse","year":"2009","unstructured":"Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39:469\u201377. https:\/\/doi.org\/10.1111\/j.1365-2222.2009.03207.x .","journal-title":"Clin Exp Allergy"},{"key":"5741_CR25","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"M van der Neut Kolfschoten","year":"2007","unstructured":"van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Mart\u00ednez-Mart\u00ednez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange. Science. 2007;317:1554\u20137. https:\/\/doi.org\/10.1126\/science.1144603 .","journal-title":"Science."},{"key":"5741_CR26","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609 .","journal-title":"J Clin Oncol"},{"key":"5741_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","volume":"2","author":"FR Brennan","year":"2010","unstructured":"Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2:233\u201355. https:\/\/doi.org\/10.4161\/mabs.2.3.11782 .","journal-title":"MAbs."},{"key":"5741_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.abb.2012.03.021","volume":"526","author":"R Jefferis","year":"2012","unstructured":"Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012;526:159\u201366. https:\/\/doi.org\/10.1016\/j.abb.2012.03.021 .","journal-title":"Arch Biochem Biophys"},{"key":"5741_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"JJMA Hendrikx","year":"2017","unstructured":"Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22:1212\u201321. https:\/\/doi.org\/10.1634\/theoncologist.2017-0167 .","journal-title":"Oncologist."},{"key":"5741_CR30","unstructured":"Sancho-Lopez A, de Graeff P, European Medicines Agency, Assessment report nivolumab EMA\/CHMP\/76688\/2015. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/opdivo-epar-public-assessment-report_en.pdf . Accessed 14 Sept 2018."},{"key":"5741_CR31","unstructured":"Food and Drug Administration. Prescribing information nivolumab. 2015."},{"key":"5741_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","volume":"164","author":"D Pluim","year":"2018","unstructured":"Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM. Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J Pharm Biomed Anal. 2018;164:128\u201334. https:\/\/doi.org\/10.1016\/j.jpba.2018.10.025 .","journal-title":"J Pharm Biomed Anal"},{"key":"5741_CR33","unstructured":"van Zwieten-Boot B, Sancho-Lopez EMA. Assessment report ipilimumab EMA\/CHMP\/557664\/. 2011."},{"key":"5741_CR34","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.4049\/jimmunol.151.7.3489","volume":"151","author":"T Lindsten","year":"1993","unstructured":"Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, et al. Characterization of CTLA-4 structure and expression on human T cells. J Immunol. 1993;151:3489\u201399.","journal-title":"J Immunol"},{"key":"5741_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1 .","journal-title":"Lancet Oncol."},{"key":"5741_CR36","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","volume":"26","author":"JS Weber","year":"2008","unstructured":"Weber JS, O\u2019Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I\/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950\u20136. https:\/\/doi.org\/10.1200\/JCO.2008.16.1927 .","journal-title":"J Clin Oncol"},{"key":"5741_CR37","volume-title":"Australian public assessment report for Ipilimumab","author":"Department of Health and Ageing Australian Government","year":"2011","unstructured":"Department of Health and Ageing Australian Government. Australian public assessment report for Ipilimumab. 2011."},{"key":"5741_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548\u201358. https:\/\/doi.org\/10.1038\/clpt.2008.170 .","journal-title":"Clin Pharmacol Ther"},{"key":"5741_CR39","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1002\/eji.1830261038","volume":"26","author":"C Medesan","year":"1996","unstructured":"Medesan C, Radu C, Kim JK, Ghetie V, Ward ES. Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. Eur J Immunol. 1996;26:2533\u20136. https:\/\/doi.org\/10.1002\/eji.1830261038 .","journal-title":"Eur J Immunol"},{"key":"5741_CR40","doi-asserted-by":"publisher","first-page":"16941","DOI":"10.1074\/jbc.M000937200","volume":"275","author":"MI Brazil","year":"2000","unstructured":"Brazil MI, Chung H, Maxfield FR. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer\u2019s disease amyloid fibrils by microglia. J Biol Chem. 2000;275:16941\u20137. https:\/\/doi.org\/10.1074\/jbc.M000937200 .","journal-title":"J Biol Chem"},{"key":"5741_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1212\/WNL.0000000000002298","volume":"86","author":"EE Benarroch","year":"2016","unstructured":"Benarroch EE. Choroid plexus--CSF system: recent developments and clinical correlations. Neurology. 2016;86:286\u201396. https:\/\/doi.org\/10.1212\/WNL.0000000000002298 .","journal-title":"Neurology."},{"key":"5741_CR42","doi-asserted-by":"publisher","first-page":"12199","DOI":"10.1523\/JNEUROSCI.3856-08.2008","volume":"28","author":"RE Hulse","year":"2008","unstructured":"Hulse RE, Swenson WG, Kunkler PE, White DM, Kraig RP. Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha. J Neurosci. 2008;28:12199\u2013211. https:\/\/doi.org\/10.1523\/JNEUROSCI.3856-08.2008 .","journal-title":"J Neurosci"},{"key":"5741_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/iid3.192","volume":"6","author":"TH Scott-Taylor","year":"2018","unstructured":"Scott-Taylor TH, Axinia S-C, Amin S, Pettengell R. Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy. Immunity Inflamm Dis. 2018;6:13\u201333. https:\/\/doi.org\/10.1002\/iid3.192 .","journal-title":"Immunity Inflamm Dis"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5741-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T21:54:27Z","timestamp":1694901267000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5741"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5741-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"7 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests related to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"519"}}